Invest in a wide range of the pharmaceutical industry
Hardman & Co Research
06-Jul-2021 / 09:30 GMT / BST
Hardman & Co research: Invest in a wide range of the pharmaceutical industry
IBT was established in 1994 to offer institutional and retail investors the opportunity to participate in global biotechnology and life science companies, from early stage development to venture capital (SV Health Investors funds) to biotechnology companies. global and multinational. The main objective of the trust is to generate capital growth, while minimizing risk, through a diversified portfolio and an experienced investment management team. Over the past five years, IBT’s net asset value has increased 62%, while the stock price has risen 92% over the same period – with superior returns usually translating into a premium on the stock. share price.
Please click on the link below for the full report:
If you are interested in meeting the company, you can register your interest by clicking on the link above
To contact us:
Hardman & Cie
Follow us on twitter @HardmanandCo
+44 20 3693 7075
Hardman & Co Research is still available free of charge after MiFID II. Please Click here read the statement.
About Hardman & Co: Over the past 25 years, Hardman has produced specialized research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are very experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our aim is to raise the profiles of companies across the UK and internationally with exceptional research, investor engagement programs and advisory services. Some of our notes were commissioned by the company that is the subject of the note; this is clearly stated in the disclaimer when this is the case.
Hardman Research Ltd, doing business as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorized and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered with Companies House under number 8256259.
Our research is intended for the professional investor community, market counterparties and sophisticated and high net worth investors as defined in the rules of regulatory bodies. It is not intended to be made available to uninformed retail investors. Anyone who is unsure of their categorization should consult their professional advisers. This research is not an offer or a solicitation to buy or sell any security. Please read the note for the full disclaimer.
Diffusion of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this advertisement.